Scoop Independent News  13th Aug 2020

Australian researchers have found that patients who received a cellular immunotherapy for the deadly brain cancer glioblastoma multiforme (GBM) in a clinical trial, on average survived longer than would have been expected without the treatment.

The team also found the treatment was safe and identified clues that will help them improve it in future. Read More